Trial Profile
A phase II study of AZD2171 [cediranib] in adult patients with neurofibromatosis type 1 and extensive plexiform and paraspinal neurofibromas
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cediranib (Primary)
- Indications Cancer; Neurofibromatosis 1; Plexiform neurofibroma
- Focus Therapeutic Use
- 21 Jul 2017 Status changed from active, no longer recruiting to discontinued.
- 21 Jul 2017 Status changed from active, no longer recruiting to discontinued.
- 21 Jul 2017 Status changed from active, no longer recruiting to discontinued.